Feedback / Questions
bimekizumab (UCB4940) - UCB
Bimekizumab: Acceptance of regulatory submission for psoriasis at the end of Q3 2020
(UCB)
-
Jul 28, 2020 -
H1 2020 Results
Regulatory
•
Psoriasis
https://www.ucb.com/_up/ucb_com_ir/documents/2020_HY_presentation_-_final.pdf
Jul 28, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious